About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.
Dyadic trades on the OTC Pink tier of the OTC market. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC market website (www.otcmarkets.com/stock/DYAI/quote).
Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Nine Months Ended
September 30, Three Months Ended
September 30, 2011201020112010Revenue: (Unaudited) (Unaudited) (Unaudited) (Unaudited) Product Related Revenue, Net
1,922,552License Fee Revenue1,017,00032,000--Research and Development Revenue1,349,985617,695535,88364,120Total Revenue7,859,0676,191,1842,575,4111,986,672Cost of Goods Sold5,004,1474,738,3921,790,9941,647,413Gross Profit2,854,9201,452,792784,417339,259Expenses:General and Administrative4,353,2823,740,0391,340,9451,105,897Sales and Marketing 807,199738,75727
|SOURCE Dyadic International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved